Pfizer/Corvas agreement focuses on NIF for stroke; Pfizer extends Neurogen agreement.
PFIZER/CORVAS AGREEMENT FOCUSES ON NIF FOR STROKE, the companies announced Oct. 16. Pfizer has licensed rights to Corvas' neutrophil inhibitory factor, which is in preclinical studies for prevention of brain tissue damage after a stroke. Corvas believes that NIF may limit the damage caused by the inflammatory response triggered by an ischemic event. NIF blocks the activation of neutrophils, their adhesion to blood vessel walls and their subsequent migration into tissue, according to Corvas.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth